Educational only — not medical advice. If you’re in crisis or thinking about suicide: call or text 988 (U.S.) or your local emergency number. Support resources. Under construction and review—see the updates log.
Published 2026-02-13 · Last reviewed 2026-02-20 · 5 references
Content sourced from FDA labeling (DailyMed) and peer-reviewed literature.
Oxazepam is a benzodiazepine indicated for the management of anxiety disorders (or short-term relief of anxiety symptoms) and for symptoms of acute alcohol withdrawal (label).
It is primarily cleared by glucuronidation to an inactive metabolite, which reduces classic CYP interaction concerns; total sedative burden remains the key safety limiter.
Oxazepam is often grouped with lorazepam and temazepam as a “LOT” benzodiazepine because it relies on glucuronidation; this can simplify use in hepatic impairment, but overdose and respiratory depression risk with opioids or alcohol remains unchanged.
For alcohol withdrawal, use protocolized monitoring and taper as symptoms resolve; carrying benzodiazepines forward as an indefinite “baseline” anxiety medication is generally avoided.
As with all benzodiazepines, dependence and withdrawal risk increase with dose and duration; chronic maintenance for generalized anxiety is generally avoided when possible.
The oxazepam compare view, review the oxazepam evidence feed, and share the oxazepam print page for safe-use counseling.
Oxazepam is often considered when hepatic impairment or complex polypharmacy makes oxidative metabolism benzodiazepines harder to manage. Time-limited plans are typical, sedative stacking is generally avoided, and psychotherapy/SSRI/SNRI approaches are prioritized for chronic anxiety.
View labelExactRefer to the Glossary entry on Neurotransmitters for background on receptor systems involved in serious mental illness.
Positive allosteric modulator of GABA-A receptors, producing anxiolytic and sedative effects through increased inhibitory neurotransmission.
Sedation, psychomotor impairment, and respiratory depression risk are driven by dose and co-administered CNS depressants.
With repeated use, tolerance and dependence can develop, with rebound anxiety/insomnia and withdrawal symptoms when stopped abruptly.
Sources: FDA/DailyMed label; benzodiazepine/anxiety guidance; ASAM alcohol withdrawal guideline.